← Trials/Trial dossier/NCT01899430
Polycystic Ovary Syndrome and Liraglutide
Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome
Lead sponsor
Asset
Liraglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
—
Enrollment
32
actual
Study population
Obesity / overweight, PCOS
Key I/E criterion
•Female
Primary endpoint
•Body weight, absolute change (kg)
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (11)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
3 endpointsThe main outcome was change in body weight.
Time frame:Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.
Body weight, absolute change (kg)
change from baseline, improvement
The secondary outcome was change in body mass index (BMI)
Time frame:Patient's body weight were measured at the base point and every four weeks during the 12 weeks of clinical trial. Patient's height was measured at the basepoint.
BMI, change
change from baseline, improvement
The secondary outcome was change in waist circumference.
Time frame:Patient's waist circumference was measured at the basepoint and every four weeks during 12 weeks of clinical trial.
Waist circumference, change
change from baseline, improvement
Glycemic / diabetes
2 endpointsThe other outcomes was changes changes in fasting concentrations of glucose.
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial.
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
Other outcome was change in fasting concentration of insulin.
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial.
change from baseline, improvement
Other clinical outcomes
5 endpointsOther outcome was change in blood concentrations of LH (luteinizing hormone).
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial
change from baseline, improvement
Other outcome was change in blood concentrations of FSH (follicle-stimulating hormone).
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial
change from baseline, improvement
Other outcome was change in blood concentration of testosterone.
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial.
Androgen, change
change from baseline, improvement
Otehr outcome was change in blood concentration in androstenedione.
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial
Androgen, change
change from baseline, improvement
Other outcome was change in blood concentration of DHEAS (dehydroepiandrosterone sulfate)
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial.
Androgen, change
change from baseline, improvement
Other (unclassified)
1 endpointOther outcome was change in blood concentrations of SHBG (sex hormone-binding globulin).
Time frame:Patient's fasting blood was drawn at the basepoint and every four weeks during the 12 weeks of clinical trial
change from baseline, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.